Progesterone (P4), commonly administered in high doses for endometrial cancer palliative management, has limitations in current delivery systems. This preliminary in vitro drug release study introduces electrospun patches to offer a new perspective on P4 delivery. The study aimed to assess the influence of the surfactant polysorbate 80 (PS80) on the release of P4 from polycaprolactone (PCL) fibers. The PS80 effects are examined to inform the fine-tuning of the fibre generation process. Patches developed, PCL wet (with PS80) and PCL dry (without PS80), showed encapsulation efficiencies of 76% and 42%, respectively. The dose levels studied are 6.1 mg for PCL wet and 4.4 mg for PCL dry samples. Molecular studies show that higher surfactant levels improved P4-polymer mixing, enhancing dissolution and release rates. Patches with PS80 released 66% of the drug in 17 h, while those without released only 51%. Release data best fit the Weibull model, showcasing promise for these patches in transdermal P4 delivery. This study offers a non-invasive option compared to traditional methods and underscores the need for further research to confirm the patches' clinical effectiveness for potential use in gynecological oncology.

中文翻译：

---

高剂量黄体酮负载 PCL-聚山梨醇酯 80 透皮纤维在妇科肿瘤学中的潜在应用

黄体酮 (P4) 通常以高剂量给药用于子宫内膜癌姑息治疗，但在当前的输送系统中存在局限性。这项初步的体外药物释放研究引入了静电纺丝贴片，为 P4 递送提供了新的视角。该研究旨在评估表面活性剂聚山梨酯 80 (PS80) 对聚己内酯 (PCL) 纤维中 P4 释放的影响。检查 PS80 效果，以便为光纤生成过程的微调提供信息。开发的贴片，PCL 湿法（含有 PS80）和 PCL 干法（不含 PS80）的封装效率分别为 76% 和 42%。研究的 PCL 湿样品剂量水平为 6.1 mg，PCL 干样品剂量水平为 4.4 mg。分子研究表明，较高的表面活性剂含量可改善 P4-聚合物的混合，从而提高溶解和释放速率。含有 PS80 的贴剂在 17 小时内释放了 66% 的药物，而不含 PS80 的贴剂仅释放了 51%。发布数据最适合 Weibull 模型，展示了这些贴剂在透皮 P4 递送中的前景。与传统方法相比，这项研究提供了一种非侵入性的选择，并强调需要进一步研究来确认贴剂在妇科肿瘤学中潜在用途的临床有效性。